DALLAS, Aug. 16, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/SOMX
Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. On March 18, 2010, the Food and Drug Administration (FDA) notified the Company that it approved its New Drug Application (NDA) for Silenor (doxepin) 3 milligram and 6 milligram tablets for the treatment of insomnia characterized by difficulty with sleep maintenance. Silenor is an oral tablet formulation of doxepin at strengths of three milligram and six milligram. Doxepin has been marketed from 75 milligram to 300 milligram per day and is indicated for the treatment of depression and anxiety. The Company's clinical development program for Silenor included four Phase III clinical trials, and the primary efficacy endpoint achieved statistical significance in each trial.
Message Board Search for SOMX: http://www.boardcentral.com/boards/SOMX
In the report, the analyst notes:
"For the second quarter of 2010, net loss applicable to common stockholders was $5.7 million, or $0.16 per share, compared with a net loss applicable to common stockholders of $6.1 million, or $0.33 per share, for the second quarter of 2009. As a development stage pharmaceutical company, SOMX had no revenues during the second quarter of 2010.
"In March 2010, the U.S. Food and Drug Administration (FDA) approved Silenor, SOMX's prescription sleep aid, for the treatment of insomnia characterized by difficulty with sleep maintenance. Sleep maintenance difficulties, defined as waking frequently during the night and/or waking too early and being unable to return to sleep, are the most commonly reported nighttime symptoms of insomnia."
To read the entire report visit: www.microstockprofit.com/lp/SOMX
See what investors are saying about SOMX at http://www.stockhideout.com
Get breaking news on SOMX at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.